Celltrion targets innovative drug development with new ADC and antibody candidates Celltrion aims for growth by venturing ...

Biohaven Ltd.(NYSE: BHVN) and  Merus N.V.(Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging ...

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its ...

Transforming the landscape of drug discovery with next-gen capabilities in obesity research, small molecule and antibody design, antibody-drug conjugate development, and interactive AI AlpaMeld Logo ...

Immuno-oncological therapies have transformed the cancer treatment landscape. They are however only effective in a subset of ...

Additionally, Daiichi Sankyo has partnered with MSD in a $22bn deal to advance ADCs targeting HER3, B7-H3, and CDH6. Each therapy in this pipeline utilises Daiichi Sankyo’s DXd technology. Enhertu and ...

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025(Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific anti ...

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a ...

Bispecific antibodies (BsAbs) are a major advancement in therapeutic oncology and hematology, capable of simultaneously engaging two distinct targets. This ...

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.